NDANASALSPRAY, METEREDPriority Review
Approved
Sep 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
NASALIDE (flunisolide) by Roche is clinical pharmacology flunisolide has demonstrated potent glucocorticoid and weak mineralocorticoid activity in classical animal test systems. First approved in 1981.
Drug data last refreshed 9h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NASALIDE (flunisolide) is a potent intranasal glucocorticoid spray approved in 1981 for allergic rhinitis and asthma. It works by direct local anti-inflammatory action on nasal mucous membranes with minimal systemic absorption at recommended doses. The drug reduces symptoms of nasal congestion, rhinorrhea, and sneezing, with improvement typically apparent within days.
LOE Approaching
Product approaching loss of exclusivity with limited linked job openings; team focus likely shifting to generic defense or brand extension strategies.
Mechanism of Action
CLINICAL PHARMACOLOGY Flunisolide has demonstrated potent glucocorticoid and weak mineralocorticoid activity in classical animal test systems. As a glucocorticoid, it is several hundred times more potent than the cortisol standard. Clinical studies with flunisolide have shown therapeutic activity…
Worked on NASALIDE at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.